Table 2 Clinical information (n = 25)
Characteristic | Value |
|---|---|
Duration of ICI therapy, days, median (IQR) | 54 (1–525) |
Number of ICI infusions at time of onset, median (IQR) | 4 (1–21) |
Time from ICI initiation to onset, months, median (IQR) | 6 (0.1–31) |
Duration of symptoms, days, median (IQR) | 5 (3–12) |
Peak biochemistry values, median (IQR) | |
White blood cell count, cells/L | 7.8 (0.7–33.0) |
Total bilirubin, mg/dL | 1.4 (0.4–36.1) |
Direct bilirubin, mg/dL | 0.9 (0.2–33.4) |
Alkaline phosphatase, IU/L | 167 (34–1281) |
ALT, IU/L | 55 (12–364) |
AST, IU/L | 47 (16–434) |
Cholecystitis clinical presentation, n (%) | |
Abdominal pain | 18 (72) |
Nausea and vomiting | 11 (44) |
Diarrhea | 3 (12) |
Fever | 5 (20) |
Positive infectious workup at time of onset, n (%) | 2 (8) |
Histopathologic examination performed, n (%) | 4 (16) |